CD79A and pneumonia: Preclinical studies in mice have demonstrated that the investigational pneumococcal vaccines when delivered mucosally, confer protection against pneumonia and nasopharyngeal colonisation eliciting both serum IgG and mucosal IgA antibodies [116–118].